Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Tks to Larry for posting on twitter for those that can't read twitter Dr Thomas heister our European sales manager says "I am happy to announce the offical partnership with #SUPERLAB in Belgrade Serbia, which will drive sales & distribution of #Novacyt’s products in Serbia, Bosnia, Macedonia, Montenegro as well as Kosovo.
In our meeting last week we completed a full product training, discussed the strategic plan for rest of 2023 and visited some end-user customers to introduce our Novacyt complete workflow solutions. We had great customers feedback, excellent exchange with our SUPERLAB colleagues and despite nearly 40°C also a little bit fun. Thanks to Jelena Paunović, Aleksandar Dimitrijević, Jovan Trbojević, Aleksandar Nesic and all others we met, for the open and furitful exchange as well as the impressive tour through #InsititutSUPERLAB. I am looking forward to a very successful long-term cooperation with SUPERLAB and to seeing you again soon."
Back to the beverages.
Just like when I posted on Abingdon board at 4-5p
Look what happened soon after.
Very used to interpreting your words Giz , have a nice weekend.
A clock is right twice a day and that's an improvement on PI101 :)
Gosh Calder kate last time you were here it was hoist the main sale etc etc.
Blooming Hendricks and fever****
Hi Gltader thank you no offence meant ..welcome to board a very interesting post ......B2HS2L post a bit further down is worth a look fella ..thank you Kaeren sometimes it's hard to interpret implications of words
Gizmo555, no offense taken. No need to apologise. I am basing my assessment on multiples of revenue, not EBITDA. I am sure you are aware, there has been M&A activities in the healthcare world in the last 3 years. Those with no sales (yet) but IP, those with sales, IP but no profits (yet), and those with the full suite. We are in the 2nd camp.
Do unto others as you would have them do unto you. Golden Rule.
Be careful of what you believe from an anon poster on here.
Umm really ? I shall choose to comment no further.
However I agree broadbrush with GL. Without doubt the acquisition of YGEN could provide the means of an immediate multiple increase on current diabolical figures. Feeling positive for the first time in a long time.
As ever time will tell. Now there is potential , organic growth has proved thus far to be non existent . Hopefully more news incoming re other M&A activity soon.
That's not sarcasm Kaeren ....it's reality of basing any investment on EBITDA ...colouring in is filling the gaps left by not including depriciation......I apologise Gltader
Gosh Gizzmo that's unlike you , sarcasm being the lowest form of wit blah blah. Disappointed.
Hi Gltader ...I like your illustration would you like someone to colour it in
P100, you could be right about revisting the 40's again.....the Ygen deal and lacklustre trading results not inspiring shareholders maybe?
GL - interesting post
if ygen - a company that seems to be run even worse than ncyt can generate that kind of revenue then one would hope that ncyt can do better....though the cash burn is still very high and with extra staff going to get worse.
the ygen portfolio looks a good addition and the bonus is that even if we lose court case then we have gained something tangible from covid. i see you gave no scenario where the gov win ? what are your thoughts on that? what valuation?
i agree that should the deal go through we will get a re-rate...just depends how much the market believes we can profit on the ygen stuff
is it me or are most of yesterday's posts gone?
Gltrader on a slow Friday my slightly less scientific view is January to December 2024 revenues should be 32 mil plus.
2025 38.5
2026 45 mil etc etc
Without further acquisitions and if we win the court case just give us a 20 pence dividend per share which is two times 10 pence.
Bullish not really but I'm off for some holiday clothes!!! and a few drinks in a couple nice places therefore banning myself until tomorrow. Gla watch them green boxes.
Well HarChris, i see you are ready to pop the Champagne. I have absolutely no interest or wish to see the SP at 10p. IMO the BOD is weak and drags its feet and the ygen deal is not yet in the bag as there is still the possibility of another bidder. The DHSC issue still pending and many predict or speculate a favourable outcome. Hopefully it would be so but no guarantees.
Based on acquisition of YGEN at valuation of circa £23m (including Thermo debt payment), and knowing the YGEN business well, here's my view (illustrative numbers only):
YGEN standalone = £23m
YGEN with capital / funding = 2-3 x £23m
YGEN with capital / funding + Novacyt installed lab channels = 3-4 x £23m
So, the completion of the acquisition alone should give an uplift to Novacyt valuation, just because of the valuation uplift from the acquired YGEN business.
As for Novacyt business:
Novacyt stand alone = £28m (c 40p prior to acquisition news) (discounted NAV due to legal dispute)
Novacyt + YGEN installed lab base = 2x above?
Novacyt with legal dispute settled at NIL either way = at least 2-3x above
Novacyt with legal dispute settled in its favour = at least 3+ x above
Bottomline, Novacyt + YGEN business should therefore give us a rerating.
And finally, if proper management injected in, expect even more fireworks.
It's a win-win deal.
PS: YGEN is growing its core business 20%+ and therefore I expect EBITDA positive. And with the synergies, will reduce cash burn in Novacyt / combined business. Growth for each non-Covid business should also get a lift from cross-selling.
Apologies if posted before.
12.12.2022 - (short notice) changes to small and medium enterprise tax credits.
https://www.shlegal.com/insights/changes-to-uk-r-d-sme-tax-credits
Did these R&D tax credit changes, - taken from the Small / Medium Enterprises and provided to Big Pharma, - catch out the likes of Novacyt (and Yourgene), to our detriment as outlined within.
Stephenson Harwood, (authors) provided legal advise to Novacyt at the 2017 IPO, the purchase of IT-IS, and are now advising with the purchase of Yourgene.
Hi props ....I could explain in detail but it wouldn't change your loss ....I'm sure others understand ......it's so simple but my autistic mind works different to yours .. ..thankfully ..don't worry fella ..it will happen again ...I don't want anyone to lose... but no one understands my jibberish . .sorry
Agreed ss. Awful rns, market reacted accordingly and anticipate further drops tomorrow to level back out the weird rise from Monday and Tuesday.
Business at usual at cash burn towers
Really bad sales and figures . This is why we are not hearing any thing on RNS it is because they are not selling anything . We were very lucky to maximise sales during covid or it would be Novacyt been bought for pennies .
Now I am hearing LR is coming on board it looks even bleaker here .
A positive DHSC result is all that is keeping my here now .
Ramblings of a nut case..
The last time you popped up the share price was 45p and you predicted 10p incoming so you can hardly act all prophetic with the share price at 60p today.
One more time suckers drawn in to buying. Incredible. Once bitten...twice bitten ....three times bitten and you never learn.
P100 - support 1 is 59p and the next line of support is 54p then 47p
given the very poor rns it seems to have held well at 59p - i suspect solely due to ygen bid.
i still suspect that the increase this week was down to some ygen holders buying in as well as maybe some (past holders?) buying in anticipation of the deal going through.
the momentum sees to have petered out and the market makers will probably want to pick up the shares that they sold on the very quick rise which probably caught them out.
so i could see it potentially dropping into low 50s in the next couple of weeks.
hard to know how the market will assess the chances of the takeover happening....seems the only deal in town and that ygen will go bust if it doesn't get over the line. the problem is convincing ygen SH at a huge losses that this is the only way forward. some might vote against in spite or thinking there are better alternatives when in reality there don't seem o be. so difficult to predict the sp movement as we near the deadline date
how much will the market value the combined portfolio is the next question...were we there at 70p or is there more to come.
i think if it does drop to 50p - that would be worth buying in for a trade. in anticipation of he deal going through
just my rambling thoughts